United Therapeutics Financials
| UTH Stock | EUR 277.30 0.60 0.22% |
United |
United Therapeutics Stock Summary
United Therapeutics competes with Novo Nordisk, CSL, CSL, Mercedes-Benz Group, and Vertex Pharmaceuticals. United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US91307C1027 |
| Business Address | 1040 Spring Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.unither.com |
| Phone | 301 608 9292 |
| Currency | EUR - Euro |
You should never invest in United Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of United Stock, because this is throwing your money away. Analyzing the key information contained in United Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
United Therapeutics Key Financial Ratios
There are many critical financial ratios that United Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that United Therapeutics reports annually and quarterly.| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Target Price | 231.89 | |||
| Number Of Employees | 965 | |||
| Beta | 0.63 |
United Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining United Therapeutics's current stock value. Our valuation model uses many indicators to compare United Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across United Therapeutics competition to find correlations between indicators driving United Therapeutics's intrinsic value. More Info.United Therapeutics is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about 0.66 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for United Therapeutics is roughly 1.51 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the United Therapeutics' earnings, one of the primary drivers of an investment's value.United Therapeutics Systematic Risk
United Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. United Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on United Therapeutics correlated with the market. If Beta is less than 0 United Therapeutics generally moves in the opposite direction as compared to the market. If United Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one United Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of United Therapeutics is generally in the same direction as the market. If Beta > 1 United Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
United Therapeutics March 14, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of United Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of United Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing United Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build United Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 14.66 | |||
| Value At Risk | (3.92) | |||
| Potential Upside | 4.67 |
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |